Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $3.1 million.

  • Crinetics Pharmaceuticals' Cash from Financing Activities fell 9462.03% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $566.6 million, marking a year-over-year increase of 1415.09%. This contributed to the annual value of $1.0 billion for FY2024, which is 15978.93% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $3.1 million for Q3 2025, which was down 9462.03% from $7.1 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Cash from Financing Activities high stood at $552.0 million for Q4 2024, and its period low was $57000.0 during Q1 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $12.7 million (2023), whereas its average is $94.1 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Cash from Financing Activities surged by 16882371.13% in 2021, and later crashed by 9992.98% in 2022.
  • Crinetics Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $163.9 million in 2021, then crashed by 99.93% to $115000.0 in 2022, then skyrocketed by 32878.26% to $37.9 million in 2023, then surged by 1355.53% to $552.0 million in 2024, then plummeted by 99.44% to $3.1 million in 2025.
  • Its Cash from Financing Activities was $3.1 million in Q3 2025, compared to $7.1 million in Q2 2025 and $4.4 million in Q1 2025.